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Sminary Frequent loss of beterozygosity (LOH) has been reported on 22q in ovarian carcinoma, implying
the prsence of a tumour-suppressor gene. The neurofibromatosis type 2 gene (NF2) at 22q12 is a plausible
candidate. Analysis of 9 of the 17 exons of NF2 by single-strand conformational polymorphism (SSCP) in 67
ovarian carcinomas did not detect any somatic mutations, suggesting that NE? is not involved in the
pathogenesis of ovarian carcinoma. LOH data support this conclusion and that the putative tumour-
suppressor gene lies distal to NF2, beyond D22S283.
Cytogenetic and allele loss studies point to the involvement
of a chromosome 22 tumour-suppressor gene in a variety of
malignancies. Loss of 22q markers has been observed in
11-38% of breast cancers (Sato et al., 1990; Chen et al.,
1992; Lindblom et al., 1993), 21-50% of colon carcinomas
(Miyaki et al., 1990; Okamoto et al., 1988) and 33% of
hepatocellular carcinomas (Takahashi et al., 1993). In
ovarian carcinoma, loss of 22q markers has been reported at
frequencies of up to 71% (Cliby et al., 1993; Dodson et al.,
1993). although others have reported lower frequencies in the
range of 25% (Sato et al., 1991; Yang-Feng et al., 1993;
Osborne & Leech. 1994). These studies have not defined a
minimum region of LOH. However, with the exception of
hepatocellular carcinomas, the 22q losses are consistent with
deletion of the region containing NF2 on 22ql2 (Rouleau et
al., 1993; Trofatter et al., 1993) and this therefore may be the
target for the LOH.
Neurofibromatosis type 2 (NF2) is an autosomal dominant
syndrome which predisposes to schwannomas, meningiomas,
ependymomas and juvenile cataracts. LOH for DNA
markers on chromosome 22 has been found in both
hereditary and sporadic tumours associated with the NF2
phenotype (Sanson et al., 1993), suggesting that NF2 is acting
as a tumour-suppressor gene. NF2 is expressed in a variety of
non-central nervous system tissues and therefore could be
implicated in tumours arising from these tissues. Although
ovarian carcinoma is not part of the NF2 syndrome, somatic
mutations in the tumour-suppressor gene NFI, for example,
have been reported in tumour types not usually associated
with the hereditary syndrome (Li et al., 1992). The strong
genetic evidence for the presence of a tumour-suppressor
gene on 22q prompted us to undertake a mutation analysis
of NF2 in ovarian carcinomas and, if appropriate, a deletion
analysis to determine the smallest region of loss.
Materials and methods
Tumour specimens and DNA extraction
Tumour and blood samples were obtained from 67 patients
undergoing primary surgery for ovarian carcinoma. Thirty-
eight of the samples have been descnrbed previously and have
been the subject of extensive molecular studies (Foulkes et
al., 1993a-c. 1994; Allan et al., 1994). The remaining 29
samples were collected from hospitals in and around
Southampton. The 67 tumours studied included 46 serous
tumours. 11 mucinous. two mixed Muillerian. seven endomet-
rioid and one granulosa cell tumour. DNA was extracted
from the tumours and blood as described by Foulkes et al.
(I993a).
Polymerase chain reactions (PCRs)
PCRs were performed on 10-200 ng of genomic DNA in a
reaction volume of 20;LI with the inclusion of 1 iLCi of
[a-32PJdCTP (Foulkes et al., 1993c) using the published PCR
cycle conditions.
SSCP anatvsis
NF2 exons were amplified with primers within surrounding
intronic sequence. Details of these primers, including the
regions amplified by each set and the PCR conditions used,
have been reported by Twist et al. (1994). Samples were
prepared for single-strand conformational polymorphism
analysis as described previously (Campbell et al., 1994) and
electrophoresis carried out at room temperature in 6% non-
denaturing acrylamide gels in the presence of 5% and 10%
glycerol.
Microsatellite analysis
The chromosome 22q primers used were D22S430 (Sainz et
al., 1993), D22S282, D22S283 and D22S274 (Weissenbach et
al., 1992). PCR products were resolved on 8% non-
denaturing polyacrylamide gels.
Results
Nine of the 17 coding exons of NF2 (exons 2, 5, 7-12 and
15) were examined for the presence of somatic mutations.
The SSCP analysis was biased toward more 5' exons since
the N-terminal region of the merlin protein is more fre-
quently associated with mutations (Deprez et al., 1994), how-
ever no mutations were detected in any of the 67 ovarian
carcinomas. The sensitivity of SSCP analysis has been shown
to be related to the size of the PCR product (Sheffield et al.,
1993). In our study, this was 188 bp, and we therefore
estimate the SSCP analysis sensitivity to be 70-75%.
In view of the absence of detectable NF2 mutations we
undertook a preliminary allelotype analysis of 37 ovarian
carcinomas (from the collection described by Foulkes et al.,
1993a-c) in order to identify tumours with partial loss of
22q, since previous studies have not enabled an assignment
of the gene to any particular region on chromosome 22. All
four 22q markers used map distal to NF2, with the most
proximal marker, D22S430, located in a region approx-
imately 300kb distal to NF2. The relative genetic and
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Figwe 1 Alelic deletion pattern for ovarian tumours 28, 72 and 91 showing partial loss of chromosome 22q. Unshaded boxes, no
LOHW black filled boxes, LOH; grey filled boxes, constitutional homozygosity. For each informative locus, the autoradiograph of
the normal (N) and tumour (T) DNA PCR is shown to the right. A genetic linkage map of the four markers used is shown to the
right of a karyogram of chromosome 22 and is based on publsbed maps (Matise et al., 1994; Buetow et al., 1994). The inter-locus
distances are in centimorgans. The position of the NF2 gene is indicated just proximal to D22S430.
cytogenetic positions of these markers are shown in Figure 1.
Twenty-three of 32 informative tumours (72%) showed loss
of one or more 22q markers. In three of these tumours
partial loss of 22q was observed (Figure 1). In tumour 28,
complete LOH was observed with D22S274 and D22S282,
while only partial LOH was seen with D22S283. The finding
was consistently found on repeated testing and therefore
might be accounted for by clonal variation. In tumour 72,
heterozygosity is clearly maintained with D22S283 and com-
pletely lost with the more distal markers. In tumour 91, there
was maintenance of heterozygosity with the most proximal
marker D22S430 but clear loss with the distal markers
D22S283 and D22S274.
LOH data suggest that a tumour-suppressor gene relevant in
ovarian, breast and colon carcinomas resides on chromosome
22, but it is unclear at this stage if the same gene is involved
in these and other malignancies. NF2, located at 22q12, is a
plausible candidate for this gene, but to date somatic muta-
tion analysis has been restricted largely to tumours of the
central nervous system (CNS). However, in two reports,
mutations were detected in the coding region of NF2 in a
total of I of 69 breast carcinomas, 6 of 17 melanomas and 2
of 64 colon carcinomas (Arakawa et al., 1994; Biachi et al.,
1994). The significance of the low frequencies of NF2 muta-
tion in the breast and colon carcinomas is unclear. However,
in this study of 67 ovarian carcinomas, the absence of NF2
mutations supports the conclusion that NF2 is not involved
in the pathogenesis of ovarian carcinoma. Although we have
not examined all the NF2 coding exons, studies in NF2-
related tumours (Rouleau et al., 1993; Deprez et al., 1994;
Rubio et al., 1994; Ruttledge et al., 1994; Twist et al., 1994)
and non-CNS tumours (Arakawa et al., 1994; Biachi et al.,
1994) have shown that mutations are distributed throughout
the gene with a bias towards more 5' exons. The distribution
of NF2 mutations is unlikely to differ significantly in ovarian
carcinomas, and given our large sample size we consider it
improbable that NF2 is the 22q ovarian carcinoma tumour-
suppressor gene.
In our preliminary allelotype study we demonstrated 72%
LOH of 22q markers, consistent with the frequencies
reported by Cliby et al. (1993) and Dodson et al. (1993).
Three tumours were identified which had retained
heterozygosity for markers proximal to NF2 but showed
LOH for more distal markers. Although some somatic dele-
tions might be the result of generalised genomic instability
unrelated to tumour pathogenesis, the finding of three
tumours with consistent losses distal to NF2, coupled with
the absence of mutations in the NF2 gene, support the con-
clusion that the 22q ovarian carcinoma tumour-suppressor
gene lies distal to NF2, beyond D22S283. Detailed deletion
mapping of 22q in an expanded set of ovarian carcinomas is
currently under way to refine the location of this gene.
Abbreviado LOH, loss of heterozygosity; NF2, neurofibromatosis
type 2; PCR, polymerase chain reaction; CNS, central nervous
system.
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